



“Identifying Bottlenecks and Using Opportunities in Contemporary Paediatric Therapeutic Research”

The Hague, Wednesday, 17 November 2004

Venue: Sociëteit De Witte
Plein 27 s' Gravenhage
2502 AN The Hague, The Netherlands

Plenary Session

- Chair: Michael Griffith
Chief Executive, Fighting Blindness; Board Member, EPPOSI, IE
- 16:00 - 16:10 Welcome
Ysbrand Poortman
Chair, EPPOSI, NL
- 16:10 – 16:30 “From concept to children: a new perspective in developing pediatric treatments”
CHMP (tbc)
- 16:30 – 16:50 “Children in the WHO Report”
Richard Laing
World Health Organization, CH
- 16:50 – 17:10 The “Critical Path” in pediatrics: the FDA perspective
Janet Whitley
Reviewing Pharmacologist, Office of Orphan Products Development, FDA, USA
- 17:10 – 18:10 **Roundtable: “The Prerequisites for Priority Medicines for Children”**
- Chair: Andrea Rappagliosi
Vice President, Corporate Health Policy & Government Relations, Serono; CH
- Patients: Mary Baker
President European Federation Neurological Associations, UK
 - Industry: Erik Tambuyzer
Senior Vice President, Corporate Affairs Europe, Genzyme; B
 - Clinical: Gérard Pons
Head Clinical Pharmacology, *Hôpital Cochin - Saint Vincent de Paul*, F

